ATE475713T1 - Trans-lentivirales vektor system - Google Patents

Trans-lentivirales vektor system

Info

Publication number
ATE475713T1
ATE475713T1 AT00984421T AT00984421T ATE475713T1 AT E475713 T1 ATE475713 T1 AT E475713T1 AT 00984421 T AT00984421 T AT 00984421T AT 00984421 T AT00984421 T AT 00984421T AT E475713 T1 ATE475713 T1 AT E475713T1
Authority
AT
Austria
Prior art keywords
present
dna encoding
trans
protein
lentiviral
Prior art date
Application number
AT00984421T
Other languages
English (en)
Inventor
John Kappes
Xiaoyun Wu
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Application granted granted Critical
Publication of ATE475713T1 publication Critical patent/ATE475713T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Control Of Vehicle Engines Or Engines For Specific Uses (AREA)
  • Electric Propulsion And Braking For Vehicles (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
AT00984421T 1999-12-14 2000-12-14 Trans-lentivirales vektor system ATE475713T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/460,548 US6555342B1 (en) 1998-06-03 1999-12-14 Fusion protein delivery system and uses thereof
PCT/US2000/034021 WO2001044481A1 (en) 1999-12-14 2000-12-14 Fusion protein delivery system and uses thereof

Publications (1)

Publication Number Publication Date
ATE475713T1 true ATE475713T1 (de) 2010-08-15

Family

ID=23829157

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00984421T ATE475713T1 (de) 1999-12-14 2000-12-14 Trans-lentivirales vektor system

Country Status (9)

Country Link
US (4) US6555342B1 (de)
EP (1) EP1244797B1 (de)
JP (1) JP4842482B2 (de)
AT (1) ATE475713T1 (de)
AU (1) AU785283B2 (de)
CA (1) CA2394261C (de)
DE (1) DE60044754D1 (de)
NZ (1) NZ519671A (de)
WO (1) WO2001044481A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1092779T3 (da) * 1999-10-11 2010-02-15 Pasteur Institut Lentiviirusvektorer til fremstilling af immunterapeutiske præparater
GB0024550D0 (de) * 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
WO2002070651A2 (en) * 2001-03-02 2002-09-12 Merck & Co., Inc. Viral reporter particles
IL160132A0 (en) 2001-08-02 2004-06-20 Inst Clayton De La Rech Methods and compositions relating to improved lentiviral vector production systems
EP1438075A4 (de) 2001-10-02 2006-04-19 Inst Clayton De La Rech Verfahren und zusammensetzungen in verbindung mit lentiviralen vektoren mit begrenzter expression und ihre anwendungen
CN1633495A (zh) * 2001-12-21 2005-06-29 奥兹基因控股有限公司 利用慢病毒载体产生基因修饰动物的方法和组合物
US20050214945A1 (en) * 2002-05-17 2005-09-29 Eastern Virginia Medical School Htlv-I tax induced killing of p53 null cancer cells
US8920808B2 (en) 2006-10-31 2014-12-30 East Carolina University Cytokine-based fusion proteins for treatment of multiple sclerosis
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
AU2010234743A1 (en) 2009-03-31 2011-10-20 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
WO2012007458A1 (en) 2010-07-12 2012-01-19 Universidad Autónoma De Barcelona Gene therapy composition for use in diabetes treatment
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University CMV glycoproteins and recombinant vectors
EP2831225A1 (de) 2012-03-26 2015-02-04 The United States of America, As Represented by the Secretary, Dept. of Health & Human Services Office of Technology Transfer Verabreichung von verkapselter rna an säugerzellen
EP2692868A1 (de) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
CN113648406A (zh) 2013-12-16 2021-11-16 美利坚合众国, 由健康及人类服务部部长代表 通过使用vlp复制子投递ii类mhc抗原的癌症免疫疗法
WO2017058923A1 (en) 2015-09-28 2017-04-06 East Carolina University Aluminum based adjuvants for tolerogenic vaccination

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE275259C (de)
GB8818020D0 (en) 1988-07-28 1988-09-01 Ici Plc Method for amplification of nucleotide sequences
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5175099A (en) 1989-05-17 1992-12-29 Research Corporation Technologies, Inc. Retrovirus-mediated secretion of recombinant products
ATE127520T1 (de) 1989-06-02 1995-09-15 Dana Farber Cancer Inst Inc Protein mit transaktivierender eigenschaft, dieses protein exprimierende vektoren, zellinien und seine verwendungen.
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
JPH05501654A (ja) 1990-07-12 1993-04-02 プレジデント　アンド　フェロウズ　オブ　ハーバード　カレッジ 霊長類レンチウイルスワクチン
JPH08500965A (ja) 1992-05-22 1996-02-06 デイナ ファーバー キャンサー インスチチュート ハイブリッドウイルス発現ベクター，その使用および新規アッセイ
WO1993025235A1 (en) 1992-06-09 1993-12-23 President And Fellows Of Harvard College Aids therapeutics based on hiv-2 vpx peptides
AU5848794A (en) 1993-02-05 1994-08-29 Regents Of The University Of California, The Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use
WO1995016705A1 (en) 1993-12-15 1995-06-22 The Trustees Of The University Of Pennsylvania Vpr receptor protein
EP0753006A4 (de) 1994-03-25 1999-04-14 Biomolecular Res Inst Ltd Die vpr- und vpx-proteine des hiv
US5861161A (en) 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
US5639619A (en) 1994-10-13 1997-06-17 Regents Of The University Of California Screening assay for anti-HIV drugs using the Vpr gene
WO1996032494A1 (en) * 1995-04-14 1996-10-17 University Of Alabama Research Foundation Fusion protein delivery system and uses thereof
US6200811B1 (en) 1996-04-02 2001-03-13 The Regents Of The University Of California Cell transformation vector comprising an HIV-2 packaging site nucleic acid and an HIV-1 GAG protein
AU7332198A (en) * 1997-03-06 1998-09-22 Klaus Uberla Lentivirus based vector and vector system
DK1076715T3 (da) 1998-05-13 2007-11-19 Genetix Pharmaceuticals Inc Lentivirale pakkeceller
US6602705B1 (en) * 1998-12-31 2003-08-05 Chiron Corporation Expression of HIV polypeptides and production of virus-like particles

Also Published As

Publication number Publication date
CA2394261A1 (en) 2001-06-21
JP2003519476A (ja) 2003-06-24
EP1244797A1 (de) 2002-10-02
US6555342B1 (en) 2003-04-29
US20110229964A1 (en) 2011-09-22
US20080233639A1 (en) 2008-09-25
WO2001044481A1 (en) 2001-06-21
US20050014260A1 (en) 2005-01-20
EP1244797B1 (de) 2010-07-28
AU2104301A (en) 2001-06-25
US7259014B2 (en) 2007-08-21
JP4842482B2 (ja) 2011-12-21
AU785283B2 (en) 2006-12-21
CA2394261C (en) 2012-09-04
EP1244797A4 (de) 2004-07-28
NZ519671A (en) 2004-10-29
DE60044754D1 (de) 2010-09-09

Similar Documents

Publication Publication Date Title
DE60044754D1 (de) Trans-lentivirales Vektor System
EP0873415A4 (de) Transfer system basierend auf einem fusionsprotein und seine anwendungen.
Grassmann et al. In vitro binding of human T-cell leukemia virus rex proteins to the rex-response element of viral transcripts
ATE298371T1 (de) Nicht-primaten lentivirale vektoren und verpackungssysteme
CY1106513T1 (el) Λεντινοϊικο τριπλο dna και οχηματα και ανασυνδυασμενα κυτταρα που περιεχουν λεντινοϊικο τριπλο dna
DK0941318T5 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
Li et al. Modulation of activity of Moloney murine leukemia virus preintegration complexes by host factors in vitro
ATE293169T1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
YU150891A (sh) Rekombinantna genetska informacija
DE69827284D1 (de) Funktionelle fragmente des hiv-1 vpr proteins and eine methode zu seiner anwendung
DE69732029D1 (de) Dna enthaltende impfstoffen
Nappi et al. Identification of a novel posttranscriptional regulatory element by using a rev-and RRE-mutated human immunodeficiency virus type 1 DNA proviral clone as a molecular trap
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
Heger et al. Multimer formation is not essential for nuclear export of human T-cell leukemia virus type 1 Rex trans-activator protein
FR2732346B1 (fr) Proteines mutees, codees par un gene env mute de lentivirus, fragments peptidiques inclus dans lesdites proteines, vecteurs d'expression exprimant lesdites proteines mutees et leurs applications
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
PT871757E (pt) Vectores virais condicionalmente replicantes e sua utilizacao
Taylor et al. A CNS-enriched factor that binds to NF-kappa B and is required for interaction with HIV-1 tat
Braddock et al. Orientation-specific cis complementation by bulge-and loop-mutated human immunodeficiency virus type 1 TAR RNAs
BR0114383A (pt) Interatuadores de canais de potássio e aplicações dos mesmos
ATE419350T1 (de) Humanes trp-ähnliches kalziumkanalprotein-2 tlcc- 2
AU2001251410A1 (en) 12303, a novel human twik molecule and uses thereof
WO2000053789A3 (de) Retrovirale expressionsvektoren auf der basis von herv-ltr-sequenzen
Barnor et al. Down regulation of human immunodeficiency virus type-1 (HIV-1) expression by Vif antisense RNA expression vectors in transfected cells

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties